Camp4 has attracted capital from investors such as Kraft Group to continue development of its drug discovery platform based on work at MIT and Harvard Medical School.
US-based drug discovery company Camp4 Therapeutics has raised $30m in a series A round from a consortium including conglomerate Kraft Group.
The round was led by Andreessen Horowitz and also featured Polaris Partners, which previously provided an undisclosed amount of seed funding.
Founded in 2016, Camp4 has built a platform that uses cellular and genetic insights to better understand how genes are controlled by signaling pathways in specific disease states.
The company builds on initial work undertaken by founders Richard Young, professor of biology at Massachusetts Institute of Technology’s Whitehead Institute, and Leonard Zon, director of the stem cell program at Boston Children’s Hospital and a professor at Harvard Medical School.
Josh Mandel-Brehm, CEO at Camp4, said: “The machinery that controls activation of the 24,000 genes in the human body can be codified by Camp4’s platform into a discrete set of combinatorial rules using signaling pathways.
“By combining novel experimental data and computational capabilities, our platform solves the control code for any gene and cell type central to disease pathology. We have already generated a high resolution 4D map of the liver and all of its associated disease genes.”
– This story first appeared on our sister site, Global Corporate Venturing.
